Medikamentöse Therapie der Endometriose – ein Update

Thomas Römer
In: Journal für Gynäkologische Endokrinologie/Schweiz · 2022 · vol. 25(4) , pp. 168–175 · doi:10.1007/s41975-022-00268-6 · W4308602368
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

This review updates current pharmacological therapies for endometriosis, highlighting progestins like dienogest as effective long-term options, GnRH agonists/antagonists as second-line treatments, and levonorgestrel IUDs for adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

The paper provides an update on drug-based therapy for endometriosis, framing clinical diagnosis and recommending primary long-term pharmacotherapy when there are no absolute indications for surgery, including adjuvant treatment after operations. It reports that combined oral contraceptives can improve dysmenorrhea but usually not other symptoms, while noting contraindications and the possibility of disease progression with their use; it emphasizes progestins—especially dienogest—as highly valued for long-term effectiveness with a favorable side-effect profile, and describes GnRH analogues (and future GnRH antagonists) as second-line options. For adenomyosis, it favors a 52 mg levonorgestrel-releasing intrauterine system. The paper does not explicitly discuss methodological limitations but presents these recommendations as an overall therapeutic update, with adenomyosis addressed as a parallel hormonal treatment topic. This paper is centrally about endometriosis — it focuses on a medication-therapy update, including how dienogest, GnRH analogues, and combined oral contraceptives are positioned for endometriosis and how hormonal therapy is used for adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (39)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0 · commercial use OK